Professor of Pediatrics (Critical Care); Director of Trainee Research, Pediatrics; Chair, Pediatric Protocol Review Committee, Human Investigations Committee; Principal Investigator, Pathobiology, Epidemiology and Interventions against Thrombotic and Hemostatic Outcomes (PEITHO) Program, Pediatrics; Visiting Professor of Pediatrics (University of the Philippines College of Medicine)
Pediatric Protocol Review Committee (PPRC)
The purpose of the Pediatric Protocol Review Committee is twofold: 1) to review the scientific validity of proposed studies in children, and 2) to ensure that appropriate and systematic measures to minimize risk to participating subjects are incorporated into the protocols; thereby, voting on and recommending a risk assessment to the Human Investigation Committee (HIC.)
For additional information regarding whether or not a protocol needs to go through the PPRC please email pprc.ycci.committees@yale.edu.
Review Criteria
All protocols that include minors as research subjects that are submitted for review to the Yale IRB or approved by the HRPP for review by an external IRB are subject to PPRC review. Protocols are triaged by risk as defined by the 21 CFR part 50, Subpart D/45 CFR part 46, Subpart D by the HRPP Intake team. Protocols are additionally triaged by study authorship by the PPRC Regulatory Analyst.
Minimal Risk Studies
Studies Authored by Principal investigator
Studies authored by a Yale Faculty Member or a Faculty Member at another academic medical institution will be assigned to review by a primary reviewer with expertise in the disease or field. If the protocol contains a statistical plan, a statistical reviewer will be assigned. If there are significant concerns during the review of the protocol, the reviewer may request that the submission is reviewed by the full PPRC board.
Minimal risk study types excluded from review include but are not limited to:
- Studies authored by Industry
- Studies that are conducted by an approved consortium
- Studies that have undergone NIH peer review
- Medical record reviews
- Banking Protocols
- Exempt research
- Surveys in minors
- Studies that are only for data collection purposes
- Interview studies
- Minimal risk imaging studies These studies will not be routed for PPRC review by the HRPP intake team. If the study is being reviewed by the Yale IRB and there are significant concerns during the course of review, the Yale IRB may request that the study is reviewed by the PPRC.
Greater than Minimal Risk
Studies Authored by Principal investigator
Studies authored by a Yale Faculty Member or a Faculty Member at another academic medical institution will be assigned to be reviewed by the Full PPRC Board. A primary reviewer with expertise in the disease or field and a statistical reviewer will be assigned to review the submission.
Studies Authored by Industry, Conducted by Approved Pediatric Consortium, or Undergone NIH Peer Review
Studies authored by Industry, conducted by an approved pediatric consortium, or undergone NIH Peer Review will be assigned to review by a primary reviewer with expertise in the disease or field. If the protocol contains a statistical plan, a statistical reviewer will be assigned. If there are significant concerns during the review of the protocol, the reviewer may request that the submission is reviewed by the full PPRC board.
Pediatric Cancer-Related Trials
Cancer-related trials that involve minors will be triaged to the Yale Cancer Center Protocol Review Committee (PRC) or PPRC by the Office of Quality Assurance and Training and PPRC Chair and/or Vice-Chair based upon appropriate expertise. Approval is only required from one of the aforementioned ancillary committees prior to IRB review.
2023 PPRC Meeting Schedule and Related Deadlines
Committee Chairs
Associate Research Scientist; Vice chair Pediatric Protocol Review Committee, Yale Center for Clinical Investigation (YCCI); ARS Representatitive, Faculty Advisory Committee for the Dean; Co-Chair DEI subcommittee for FAC , Yale School of Medicine; Chair of the A&P and Mentoring ARS Committee, Yale Child Study Center; Member of the FAC executive committee, Yale School of Medicine; Member Human Investigation Committee 4-B, Yale HRPP
Dr. Landeros-Weisenberger graduated medicine from La Salle University in Mexico City, Mexico; and did her training in Psychiatry at the Hospital Espanol and the Universidad Nacional Autonoma de Mexico (UNAM) in the same city. After graduating, she came to Yale University through the American Psychiatric Association (APA) Minority Training grant (PMRTP) to do her research fellowship under the mentorship of Dr. James F. Leckman at the Yale Child Study Center; focusing on novel evidence-based psychotherapeutic interventions for mental disorders cross the lifespan. She has expertise in assessment of mood disorders, Tourette syndrome, obsessive compulsive disorder, trichotillomania and anxiety disorders, among others. She also has expertise conducting and implementing clinical trials in these same conditions both with industry and NIH. She enjoys teaching medical students in these disorders and training them in evidence-based techniques. She currently serves as a Vice-chair of the Pediatric Protocol Review Committee (PPRC) and is an elected member to the dean's Faculty Advisory Council (FAC) where she Chairs the Associate Research Scientist (ARS) subcommittee and is co-chair of the DEI subcommittee. She is a new member of the Yale Human Investigation Committee 4-B. She is a mother of three and is constantly searching for the ever-elusive work-life balance.